Click here if you are having trouble viewing this message.

August newsletter

In this newsletter:

Register for our webinar and explore price and access implications of cost-utility and budget impact methodologies
Find out how we have worked with you to support industry growth in our Annual Review 2018
See what additional funding will mean for CGT Catapult and the Catapult network

This month we published our Annual Review 2018 where you can take a look at the projects we have been working on over the past year and the impact we have had so far in the building the advanced therapies ecosystem and the UK industry. We also welcomed a delegation from HM Treasury to our development laboratories in Guy's Hospital, London.

It was also announced that the UK Government have granted the Catapult Network an additional £780m in funding. The additional funding will support the CGT Catapult in its mission of providing end-to-end support to businesses and organisations to translate early-stage research into commercially viable and investable cell and gene therapies.

Whether you will be in Europe, US or Japan, we look forward to meeting you at one of our upcoming events. Finally, sign up to our upcoming webinar and explore implications of the cost-utility and budget impact methodologies with our health economics team.

Share this email on social media

News

Webinar: Implications of the cost-utility and budget impact methodologies
Explore the potential price and access implications of the country-specific differences in cost-utility and budget impact analyses, using the example of a novel gene therapy in Parkinson’s disease.
Register here

Annual Review 2018 highlights work of CGT Catapult
See an overview of our work over the past year and the impact that we have had so far in the building the advanced therapies ecosystem and the UK industry.
Annual Review 2018

Additional funding for CGT Catapult to support mission
Additional funding will support the CGT Catapult in its mission of providing end-to-end support to organisations to translate early-stage research into commercially viable and investable therapies.
Read more

HM Treasury special advisors visit CGT Catapult
During the visit the special advisors found out more about the innovative projects we are working on and how we are supporting the cell and gene therapy industry. They were also treated to a tour of the CGT Catapult development labs.
See our facilities

Where to meet the team

04-07 September 2018, Boston, MA
Cell and Gene Therapy Bioprocessing and Commercialisation
Dr Tristan Thwaites, Lead Technical Scientist at Cell and Gene Therapy Catapult, will be bringing practical input to an expert panel on the importance of automation in the commercialisation of cell and gene therapies. More information on the event.

A number of members of the CGT Catapult Business Development team will also be in attendance, if you would like to meet with them please get in touch.

10-12 September 2018, London, UK
Phacilitate Leaders Europe
Hear Chief Clinical Officer, Dr Jacqueline Barry, offer expert insight on partnering with European clinical centres of excellence as she moderates the workshop on 11 September, 11:30am.

Take a deep dive into process control with Chief Operating Officer, Dr Stephen Ward, as he asks how can we increase quality through a comprehensive process control strategy? 11 September, 11:30am.

More information on Phacilitate leaders Europe

+44 (0) 203 728 9500
12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT

The Cell and Gene Therapy Catapult takes your data very seriously, you can read how we may use it in our privacy policy. If you no longer want to hear from us unsubscribe here.